Introduction to Perivascular Epithelioid Cell Tumors

Perivascular epithelioid cell tumors, or PEComas, represent a unique family of mesenchymal neoplasms that remain relatively obscure in the broader oncological landscape. These tumors are characterized by their distinct histological appearance and a specific immunophenotype, typically co-expressing melanocytic markers like HMB-45 and smooth muscle markers such as actin. While many cases are sporadic, a substantial proportion are historically linked to mutations in the TSC1 or TSC2 genes, leading to the overactivation of the mechanistic target of rapamycin (mTOR) pathway. However, recent advances in molecular pathology have identified a distinct subset characterized by fusions involving the transcription factor E3 (TFE3) gene. This discovery has fundamentally shifted our understanding of TFE3-rearranged PEComa management, as these tumors often behave more aggressively than their TSC-mutant counterparts. Specifically, TFE3-rearranged variants tend to occur in younger patients and frequently lack the typical association with tuberous sclerosis complex. Because they arise from an alternative oncogenic mechanism, their clinical course and response to pharmacological agents differ significantly from classic presentations. Understanding these molecular nuances is paramount for clinicians, as misidentification can lead to suboptimal therapeutic choices and poor patient outcomes.

Diagnostic Challenges and Radiographic Presentation

The clinical presentation of PEComas is often nonspecific, frequently mimicking more common malignancies depending on the primary site of involvement. In the liver, for instance, these tumors can easily be mistaken for hepatocellular carcinoma or metastatic disease, especially when they present as large, hypervascular masses. Patients may report vague symptoms such as fatigue, unintended weight loss, or abdominal discomfort. Radiographically, PEComas often manifest as well-circumscribed, heterogeneous lesions on computed tomography or magnetic resonance imaging. However, when pulmonary nodules or lymph node involvement are present, the diagnostic complexity increases exponentially. In the case of a 37-year-old woman with hepatic and pulmonary involvement, the presence of multisystem disease initially raised concerns about a highly aggressive metastatic process. Consequently, imaging alone is rarely sufficient to establish a definitive diagnosis. Physicians must rely on a high index of suspicion and comprehensive tissue analysis to distinguish these rare entities from other clear cell neoplasms. Furthermore, the rarity of the condition means that many radiologists and clinicians may not initially consider PEComa as a primary differential diagnosis. Therefore, a multidisciplinary approach involving expert pathologists and radiologists is essential to navigate the diagnostic pitfalls associated with this rare disease.

Pathological Characteristics and Molecular Subtyping

Pathological evaluation remains the cornerstone of definitive diagnosis for PEComas. Histologically, TFE3-rearranged tumors often display a nested or alveolar growth pattern composed of large epithelioid cells with abundant clear or eosinophilic cytoplasm. While they share some features with classic PEComas, they frequently show reduced or absent expression of smooth muscle markers, which can complicate the initial immunohistochemical screening. Instead, strong and diffuse nuclear staining for the TFE3 protein is a suggestive marker for this molecular subset. Nevertheless, it is critical to note that TFE3 immunoreactivity is not entirely specific and can occasionally be seen in other tumors. For a precise diagnosis, molecular confirmation through fluorescence in situ hybridization or next-generation sequencing is highly recommended. These advanced techniques can identify the specific fusion partners involved, such as SFPQ or ASPSCR1, which are common in these rearrangements. This molecular differentiation is vital because it separates PEComas driven by TSC mutations from those driven by TFE3 fusions. As the pathology community refines these categories, it becomes increasingly clear that TFE3-rearranged PEComa management must be tailored to the specific genetic driver of the tumor rather than relying solely on morphological similarities.

Navigating TFE3-rearranged PEComa Management

Effective TFE3-rearranged PEComa management requires a nuanced understanding of the tumor’s resistance to conventional therapies. For years, mTOR inhibitors like sirolimus and everolimus have served as the backbone of systemic treatment for advanced PEComas, primarily because of the high prevalence of TSC1/TSC2 mutations in the classic variant. However, clinical evidence increasingly suggests that TFE3-rearranged tumors are largely insensitive to these agents. This resistance occurs because the TFE3 fusion acts as an independent oncogenic driver that does not necessarily rely on the mTOR signaling pathway for cell proliferation and survival. Consequently, when clinicians encounter a patient with disease progression despite mTOR inhibition, they must quickly reassess the molecular profile of the tumor. In many instances, the failure of first-line targeted therapy underscores the aggressive nature of the TFE3 subset. Therefore, early molecular subtyping is not just a diagnostic luxury; it is a clinical necessity that informs whether standard protocols are likely to succeed. While surgical resection remains the preferred treatment for localized lesions, the management of metastatic or unresectable TFE3-rearranged disease remains an area of active research with no universally established standard of care beyond clinical trial enrollment.

Surgical Outcomes and Systemic Resistance

Surgical intervention is often the first line of defense for patients presenting with large, localized PEComas. For example, a partial hepatectomy can provide complete local control of a primary liver lesion, potentially alleviating symptoms and reducing the overall tumor burden. However, the aggressive biology of TFE3-rearranged tumors often leads to rapid systemic progression even after successful surgery. In the reported case, despite the complete resection of the hepatic mass, the disease continued to advance in the lungs, lymph nodes, and bones. This pattern of progression highlights the high metastatic potential and the inadequacy of localized treatment alone for this molecular subtype. Furthermore, the subsequent use of mTOR inhibitors failed to arrest the growth of the remaining lesions, reinforcing the clinical observation of inherent systemic resistance. This scenario presents a significant therapeutic dilemma for oncologists. The lack of response to standard targeted therapy necessitates the exploration of alternative regimens, which may include cytotoxic chemotherapy or other targeted inhibitors. Unfortunately, traditional chemotherapy has historically shown limited efficacy in PEComas, leaving a significant gap in the treatment armamentarium for these patients. Consequently, the management of recurrent or metastatic disease after surgery remains one of the most challenging aspects of caring for individuals with this rare malignancy.

Future Directions and Emerging Targeted Therapies

As the limitations of mTOR inhibitors in TFE3-rearranged disease become more apparent, the focus of research is shifting toward identifying novel therapeutic targets. Some early evidence suggests that anti-angiogenic agents, such as VEGFR tyrosine kinase inhibitors, might offer clinical benefit. For instance, drugs like apatinib or sorafenib have shown promise in stabilizing disease in some case reports where mTOR inhibitors have failed. Additionally, given the structural and molecular similarities between TFE3-rearranged PEComas and alveolar soft part sarcomas, there is growing interest in exploring MET inhibitors and immune checkpoint inhibitors. The integration of comprehensive molecular profiling into routine clinical practice is essential to facilitate the identification of these alternative targets. Moreover, international collaboration and the creation of centralized registries are vital to gather sufficient data on this rare patient population. These efforts will hopefully lead to the development of standardized guidelines that prioritize molecular subtyping from the outset. Ultimately, the goal is to move toward a more personalized approach where TFE3-rearranged PEComa management is guided by the unique genetic vulnerabilities of each tumor. This evolution in care is necessary to improve the currently guarded prognosis for patients facing this aggressive and complex mesenchymal neoplasm.

Frequently Asked Questions

What defines the molecular difference between classic and TFE3-rearranged PEComas?

Classic PEComas typically harbor mutations in the TSC1 or TSC2 genes, which lead to constitutive activation of the mTOR signaling pathway. In contrast, TFE3-rearranged PEComas involve fusions of the TFE3 gene, often resulting in distinct morphological features and an absence of the typical TSC mutations. Because of this molecular divergence, TFE3-rearranged variants frequently do not respond to mTOR inhibitors, which are otherwise highly effective in managing classic perivascular epithelioid cell tumors.

Why is immunohistochemical staining alone sometimes insufficient for diagnosing TFE3-rearranged PEComas?

While immunohistochemistry can identify melanocytic and smooth muscle markers characteristic of PEComas, it may not reliably distinguish between the various molecular subtypes. TFE3 protein expression can sometimes be observed in tumors without actual gene rearrangements, leading to potential diagnostic confusion. Therefore, experts recommend using fluorescence in situ hybridization or next-generation sequencing to confirm the presence of TFE3 fusions. These advanced molecular techniques ensure diagnostic accuracy, which is essential for determining the most appropriate therapeutic strategy.

What are the current therapeutic options for patients with TFE3-rearranged PEComas who fail mTOR inhibition?

When patients with TFE3-rearranged PEComas show resistance to mTOR inhibitors, the therapeutic options become significantly more limited. Cytotoxic chemotherapy regimens generally provide minimal benefit, leading researchers to explore alternative targeted therapies and immunotherapy. Some studies suggest that VEGFR inhibitors or other tyrosine kinase inhibitors might offer some benefit, though robust clinical data are still lacking. Consequently, clinical trial enrollment and comprehensive molecular profiling are highly encouraged to identify novel targets that might effectively manage these aggressive neoplasms.

Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice. Always seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition. The inclusion of any specific treatment or medication does not imply endorsement. Refer to the latest local and national guidelines for clinical practice.

References

Chahine S et al. TFE3-rearranged PEComa with hepatic and pulmonary involvement: diagnostic challenges and resistance to mTOR-targeted therapy. J Cancer Res Clin Oncol. 2026 Jul 05. doi: 10.1007/s00432-026-06556-z. PMID: 42402094.

Argani P et al. Perivascular epithelioid cell tumors (PEComas) harboring TFE3 gene rearrangements lack the TSC2 alterations characteristic of conventional PEComas: further evidence for a biological distinction. Am J Surg Pathol. 2012; 36(5): 783-794.

Bleeker JS et al. Perivascular epithelioid cell tumors (PEComas): a review of emerging therapeutic targets. Sarcoma. 2012; 2012: 541905.